Ketamine

Neuregulin signaling mediates the acute and sustained antidepressant effects of subanesthetic ketamin

This rodent study (n=50) investigated the signaling pathways associated with the rapid antidepressant effects of ketamine (10mg/kg) and found a novel neural plasticity-based mechanism implicated in its acute and sustained effects.

Authors

  • Chen, L.
  • Grieco, S. F.
  • Holmes, T. C.

Published

Translational Psychiatry
individual Study

Abstract

Introduction: Subanesthetic ketamine evokes rapid antidepressant effects in human patients that persist long past ketamine's chemical half-life of ~2 h. Ketamine's sustained antidepressant action may be due to modulation of cortical plasticity.Methods: To determine if the ketamine-mediated amelioration of depression-like behaviors depends on NRG1/ErbB4 signaling in PV inhibitory interneurons, we tested the antidepressant effects of ketamine in the FST using mice, by manipulating NRG1/ErbB4 signaling.Results: We find that ketamine ameliorates depression-like behavior in the forced swim test in adult mice, and this depends on parvalbumin-expressing (PV) neuron-directed neuregulin-1 (NRG1)/ErbB4 signaling. Ketamine rapidly downregulates NRG1 expression in PV inhibitory neurons in mouse medial prefrontal cortex (mPFC) following a single low-dose ketamine treatment. This NRG1 downregulation in PV neurons co-tracks with the decreases in synaptic inhibition to mPFC excitatory neurons for up to a week. This results from reduced synaptic excitation to PV neurons, and is blocked by exogenous NRG1 as well as by PV targeted ErbB4 receptor knockout.Discussion: Thus, we conceptualize that ketamine's effects are mediated through rapid and sustained cortical disinhibition via PV-specific NRG1 signaling. Our findings reveal a novel neural plasticity-based mechanism for ketamine's acute and long-lasting antidepressant effects.

Unlocked with Blossom Pro

Research Summary of 'Neuregulin signaling mediates the acute and sustained antidepressant effects of subanesthetic ketamin'

Introduction

Slow onset of effect is a major limitation of conventional antidepressants, typically requiring 3–6 weeks to show clinical benefit. Subanesthetic doses of ketamine have attracted interest because they produce rapid antidepressant effects in treatment-resistant patients that persist long after the drug's chemical half-life (~2 h). Previous work links ketamine to changes in cortical excitatory/inhibitory (E/I) balance and to induction of adult cortical plasticity, but the precise cellular and molecular mechanisms that translate a single low dose into sustained behavioural improvement remain unclear. Grieco and colleagues set out to test whether ketamine's rapid and sustained antidepressant actions are mediated by neuregulin-1 (NRG1)/ErbB4 signalling in parvalbumin-expressing (PV) inhibitory interneurons in higher-order cortex, specifically the medial prefrontal cortex (mPFC). Building on prior findings in visual cortex, the study examines behaviour (forced swim test), in vivo population calcium imaging, cell-type-specific mRNA changes, synaptic physiology (IPSCs and excitatory inputs to PV cells), and pharmacological and genetic manipulations of NRG1/ErbB4 signalling to link molecular, cellular and circuit-level changes to ketamine's antidepressant-like effects.

Methods

The study used adult mice and combined behavioural, imaging, molecular and electrophysiological methods. A single subcutaneous dose of subanesthetic ketamine (10 mg/kg, s.c.) was used for most in vivo experiments; the ketamine metabolite (2R,6R)-hydroxynorketamine (HNK; 10 mg/kg, s.c.) was also tested. Exogenous NRG1 (recombinant EGF core domain of NRG1-β1) was administered subcutaneously at 1 µg per mouse to probe NRG1/ErbB4 dependence; bath application of NRG1 (5 nM) was used in slice experiments. Pharmacological blockade of ErbB receptors used PD158780 (10 mg/kg, s.c.), and MK-801 (0.1 mg/kg) was used to probe acute NMDAR antagonism. PV-Cre; ErbB4 fl/fl conditional knockout mice were generated to selectively remove ErbB4 from PV interneurons. Animals were randomly assigned to treatment groups and behavioural testing was performed during fixed hours. Behaviour was assessed using the forced swim test (FST): mice were habituated, then videotaped for 6 min and immobility quantified in the final 4 min; ANY-MAZE software and blind manual scoring were used. In vivo population calcium imaging of mPFC excitatory neurons used stereotaxic AAV-CaMK2a-GCaMP6f expression, GRIN lens implantation and head-mounted miniscopes; videos were processed with motion correction and CNMF-E deconvolution, and a linear mixed effects (LME) model accounted for nested repeated measures (cells within mice). Cell-type-specific mRNA changes were measured using translating ribosome affinity purification (TRAP) from PV-Cre; fsTRAP or Emx1-Cre; fsTRAP mice; pooled mPFC tissue (PV: both cortices from 5 mice per sample; Emx1: both cortices from 2 mice per sample) was used to generate n = 1 per pooled sample before RNA extraction. qPCR probed NRG1 (total transcripts) and ErbB4 with GAPDH normalisation. Immunohistochemistry quantified pCREB levels in cortical layers. Electrophysiology involved whole-cell recordings in mPFC slices: electrically evoked IPSCs in L2/3 pyramidal neurons were recorded by stimulating L5 feedforward projections, and laser-scanning photostimulation (LSPS; glutamate uncaging) mapped excitatory inputs to individually recorded L2/3 PV interneurons. Drug applications in slices were applied via ACSF (20 min) and washouts were performed. Statistical analyses included ANOVA, t-tests, nonparametric alternatives when appropriate, LME models for repeated measures, and Bonferroni corrections for multiple comparisons.

Results

Behavioural dependence on NRG1/ErbB4: A single subanesthetic ketamine injection (10 mg/kg, s.c.) produced antidepressant-like effects in the FST at both 30 min and 24 h after treatment, as expected. Subcutaneous administration of exogenous NRG1 (1 µg/mouse) on its own had no effect in the FST, but it significantly blocked ketamine's behavioural effect at both 30 min and 24 h (one-way ANOVA overall p = 0.0069 for 30 min and p = 0.0289 for 24 h; two-sample comparisons ketamine+saline vs saline and ketamine+NRG1 vs ketamine+saline reached significance). HNK (10 mg/kg, s.c.) produced an antidepressant-like effect at 24 h that was likewise blocked by NRG1 (one-way ANOVA overall p = 0.0031). Genetic removal of ErbB4 from PV interneurons (PV-Cre; ErbB4 fl/fl) prevented ketamine's antidepressant effect in the FST while control ErbB4 fl/fl mice remained responsive (two-way ANOVA overall p = 0.0033). Pharmacological ErbB blockade with PD158780 produced improved FST immobility at 2 h and 24 h after administration (one-way ANOVA overall p = 0.0421), consistent with the involvement of ErbB signalling in regulating behaviour. In vivo excitatory neuron activity: Longitudinal miniscope imaging of AAV-CaMK2a-GCaMP6f-expressing mPFC excitatory neurons tracked 1,332 neurons from 12 mice and showed that ~95% of those neurons increased activity 24 h after ketamine. Calcium event frequency increased significantly (LME overall p = 3.66 × 10^-5), as did peak amplitudes (p = 0.0003) and integrated event amplitudes (p = 0.0001). Locomotor activity did not differ 24 h after ketamine, indicating the imaging changes were not due to altered gross movement. Cortical inhibition and disinhibition: Acute bath-applied ketamine (100 µM) or in vivo MK-801 pre-treatment did not alter evoked inhibitory postsynaptic currents (IPSCs) in L2/3 pyramidal neurons, suggesting acute NMDAR antagonism was insufficient to change this inhibitory drive in slices. In contrast, in vivo subanesthetic ketamine produced dramatic reductions in electrically evoked IPSC amplitudes in L2/3 pyramidal neurons beginning at 1 h and persisting at 24, 48 and 72 h, with a return to baseline by 1 week (one-way ANOVA overall p = 1.77 × 10^-20; two-sample t tests: 1 h p = 5.01 × 10^-9, 24 h p = 8.54 × 10^-8, 48 h p = 1.69 × 10^-8, 72 h p = 1.04 × 10^-8, 1 week p = n.s.). HNK (in vivo) also decreased pyramidal IPSCs at 24 h. Acute bath application of NRG1 (5 nM) reversed the ketamine- and HNK-induced disinhibition in slices; NRG1 had no effect on IPSCs in untreated control slices and the reversal was lost on washout. Neither ketamine nor NRG1 substantially changed spontaneous IPSCs or paired-pulse ratios in the reported data. PV-specific NRG1/ErbB4 changes: TRAP followed by qPCR showed higher baseline NRG1 expression in PV interneurons than in Emx1+ excitatory neurons. Ketamine induced a sustained downregulation of NRG1 mRNA selectively in PV cells: one-way ANOVA overall p = 0.0006, with ketamine vs saline adjusted two-sample comparisons significant at 24 h (p = 0.0027) and 48 h (p = 0.0002) and returning toward baseline by 72 h/1 week in the extracted data. ErbB4 mRNA was markedly enriched in PV neurons at baseline and did not show parallel decreases after ketamine; an increase was reported at 1 week (one-way ANOVA overall p = 0.0018; ketamine vs saline at 1 week p = 4.55 × 10^-4). Immunostaining showed that phosphorylated CREB (pCREB), a marker associated with increased excitatory neuron activity, was significantly elevated in L2/3 excitatory neurons following ketamine and that this elevation was sustained for up to 2 days; PV interneuronal pCREB remained low and unchanged. Excitatory inputs to PV neurons: LSPS mapping in mPFC slices revealed robust baseline excitatory inputs to L2/3 PV interneurons from L2/3 and L5. Following in vivo ketamine, excitatory drive to PV cells was dramatically reduced at 1, 24, 48 and 72 h and recovered by 1 week. Bath application of NRG1 robustly restored both synaptic input currents and direct uncaging responses in PV neurons from ketamine-treated mice at the 1–72 h time points, while having little effect on control PV cells. Statistical tests for input strength and uncaging responses showed highly significant treatment and time effects with adjusted pairwise p-values often < 10^-3 for the ketamine vs control and NRG1 rescue comparisons. Bath-applied NRG1 did not change resting membrane potential or intrinsic excitability of PV cells in either condition.

Discussion

Grieco and colleagues interpret their findings as identifying PV neuron-directed NRG1/ErbB4 signalling in mPFC as a key molecular and circuit mediator of both the rapid and sustained antidepressant-like effects of subanesthetic ketamine. They link a single ketamine exposure to a rapid and sustained downregulation of NRG1 mRNA in PV interneurons, a loss of excitatory drive to those cells, and consequent cortical disinhibition and increased activity of excitatory neurons — changes that persist well beyond ketamine's chemical presence and that co-track with behavioural improvement in the FST. The authors position this mechanism within the broader literature that implicates ketamine-induced plasticity and downstream molecular cascades (BDNF, TrkB, mTOR, GSK3) in antidepressant responses, arguing that the present data provide a circuit-level step that may precede or interact with those signalling pathways. They further emphasise that the disinhibitory mechanism appears independent of acute NMDAR antagonism in slices, since bath-applied ketamine or MK-801 did not reproduce the in vivo disinhibitory effects. Acknowledged limitations include an incomplete understanding of the precise molecular mechanism by which ketamine downregulates NRG1 in PV neurons and the possibility that a specific NRG1 isoform might be responsible. The investigators also note that they did not directly measure inhibitory inputs onto PV cells and that systemic ketamine likely acts across multiple brain regions beyond mPFC, which could contribute to behavioural outcomes. They acknowledge critiques of the FST as a model of depression-like behaviour but argue that their combined molecular, circuit and behavioural data support a PV NRG1/ErbB4-directed mechanism that promotes cortical plasticity relevant to antidepressant action. Implications discussed by the authors include framing ketamine's sustained behavioural effects as arising from a defined plasticity mechanism — PV-specific loss of NRG1/ErbB4 signalling leading to transient removal of excitatory drive onto PV interneurons, cortical disinhibition and facilitation of plasticity — and they suggest this pathway could be a target for future mechanistic studies and potentially therapeutic modulation.

View full paper sections

INTRODUCTION

One of the major limitations of the frontline drugs for treating clinical depression is their very slow onset of effectiveness, typically between 3 and 6 weeks. Ketamine has gained widespread attention for its potential to treat psychiatric disorders at subanesthetic doses, particularly in human patients who are resistant to classical treatments for depression. Though ketamine is considered to be an NMDA receptor antagonist at high doses, its mechanism of action at subanesthetic doses is unknown. Ketamine's chemical half-life time is only ~2 h, yet a single treatment results in antidepressant effects that last up to ~2 weeks, well past the chemical persistence of ketamine or its metabolites. A potential explanation for these acute and long-lasting effects is that ketamine modulates neural circuit plasticity. This is supported conceptually by findings that behavioral depression results from a failure of neural plasticity. Administration of antidepressants, such as fluoxetine and ketamine, induce cortical plasticity in adult animals. But whether and how ketamine induces cortical plasticity in a rapid and sustained fashion is unknown. Ketamine modulates the excitatory/inhibitory (E/I) balance in cortical circuits. This change in E/I balance may initiate long-lasting cortical plasticity in higher-order association cortex such as prefrontal cortex (PFC). There are reductions in synapse function in the PFC of both depressed patients and rodents with depression-like behavior. And substantial evidence shows that a subanesthetic dose of ketamine increases synaptic activity in mPFC. Our previous work shows that genetic silencing of parvalbumin-expressing (PV) interneuron activity results in cortical disinhibition and promotes cortical plasticity beyond the visual development critical period. Work from our group and others has indicated that neuregulin-1 (NRG1) signaling through PV neurons regulates developmental and adult visual cortical plasticity. PV neurons have strong and concentrated NRG1 expression; this distinguishes them from surrounding putative excitatory neurons. NRG1's receptor ErbB4 is highly restricted to PV neurons. Downregulation of NRG1/ErbB4 signaling by PV interneurons results in a rapid retraction of excitatory inputs to PV cells, resulting in cortical disinhibition, and the initiation of cortical plasticity. Recently, we discovered that a subanesthetic dose of ketamine induces adult visual cortical plasticity by downregulating NRG1 signaling in PV inhibitory neurons in adult mice. This motivated us to test the hypothesis that the antidepressant effects of a single subanesthetic ketamine treatment are due to its modulation of NRG1-directed signaling in PV inhibitory neurons in higher association cortex including PFC. In the present study, we find that ketamine's antidepressant effects, as measured in the forced swim test (FST), depend on PV neuron-directed NRG1/ ErbB4 signaling. We find that a single dose of subanesthetic ketamine induces acute and sustained downregulation of NRG1 expression in PV inhibitory neurons in medial prefrontal cortex (mPFC), resulting in sustained PV excitatory input loss and cortical disinhibition. Our study establishes molecular, cellular, and circuit mechanisms for ketamine's antidepressant actions.

ANTIDEPRESSANT EFFECTS OF KETAMINE DEPEND ON NRG1/ ERBB4 SIGNALING

To determine if the ketamine-mediated amelioration of depression-like behaviors depends on NRG1/ ErbB4 signaling in PV inhibitory interneurons, we tested the antidepressant effects of ketamine in the FST using mice, by manipulating NRG1/ErbB4 signaling. The FST measures depressive-like behavioral states and strongly predicts antidepressant efficacy. The reduction in depression-like behavior using the FST after a subanesthetic dose of ketamine is the most well-characterized behavioral measure of ketamine's antidepressant effect to date in rodents. The antidepressant effects of ketamine for the FST behavioral despair test are well established. A single subanesthetic ketamine treatment (10 mg/kg, subcutaneous, s.c.) shows significant antidepressant effects for the FST as measured by increased duration of immobility at 30 min and 24 h after treatment (Fig.). To determine if NRG1 signaling underlies ketamine's antidepressant effects, animals were treated with exogenous NRG1 at a dose we have previously found effective in the context of modulating visual cortical plasticity. We used recombinant NRG1 containing only the EGF core domain of NRG1-β1. This form of NRG1 has been shown previously to penetrate the blood-brain barrier and to functionally activate ErbB4 in the cortex. Subcutaneous injection of NRG1 alone has no effects on performance in the FST. Exogenous NRG1 (1 µg per mouse, s.c.) significantly blocks the antidepressant effect of ketamine in both the acute 30 min and the long-term 24 h ketamine treatment groups (Fig.) (Fig.. One-way ANOVA: overall p = 0.0069. Two-sample t test: ketamine + saline vs saline p = 0.0411, ketamine + NRG1 vs ketamine + saline p = 0.0066) (Fig.. One-way ANOVA: overall p = 0.0289. Two-sample t test: ketamine+saline vs saline p = 0.0257, ketamine + NRG1 vs ketamine + saline p = 0.0351). We then tested the effects of a single treatment with (2R, 6R)-hydroxynorketamine (HNK) (10 mg/kg, s.c.), the major metabolite of ketamine which has previously been shown to mediate ketamine's effects and which does not appear to have abuse potential. HNK shows significant antidepressant effects for the FST performed 24 h after treatment, and HNK's effect is blocked by NRG1 treatment (Fig.. One-way ANOVA: overall p = 0.0031. Two-sample t test: HNK + saline vs saline p = 0.0076, HNK + NRG1 vs HNK + saline p = 0.0071). Since exogenous NRG1 treatment prevents ketamineinduced antidepressant effects, we tested specifically if NRG1/ErbB4 signaling by PV interneurons is required for the antidepressant effect of ketamine in the FST. This was done using PV-Cre; ErbB4 fl/fl mice in which ErbB4 expression is selectively removed in PV-positive interneurons. The absence of ErbB4 in PV interneurons prevents ketamine's antidepressant effects in the FST, whereas in control mice ketamine is still effective (Fig.. Two-way ANOVA: overall p = 0.0033. Two-sample t test: saline vs ketamine (ErbB4 fl/fl ) p = 0.0041, saline vs ketamine (PV-Cre; ErbB4 fl/fl ) p = n.s.). We further explored the antidepressant dependence of ketamine action on ErbB4 signaling using the pharmacological ErbB antagonist PD158780, which acutely blocks ErbB4 signaling. FST immobility significantly improves 2 hours and 24 hours following PD158780 treatment (Fig., Oneway ANOVA: overall p = 0.0421. Two-sample t test: PD158780 vs saline, 30 min. p = n.s., 2 h p = 0.0098, 24 h p = 0.0395). These results are consistent with previous reports of the antidepressant effect of ketamine, and provide new evidence that NRG1/ErbB4 signaling in PV interneurons contributes to ketamine's antidepressant actions.

KETAMINE INCREASES NEURAL ACTIVITY OF MPFC EXCITATORY NEURONS IN VIVO

To determine the effect of ketamine on cortical activity, we performed population calcium imaging of excitatory neurons in vivo in mPFC using head-mounted miniscopes. We selectively expressed GCaMP6f in mPFC excitatory neurons by using stereotaxic guided injection of AAV-CaMK2a-GCaMP6f into mouse mPFC (Fig.). We longitudinally tracked and measured the activity of mPFC excitatory neurons. We first probed baseline population calcium activities at single cell resolution for mPFC excitatory neurons, then in the same neurons we measured the effects of ketamine 24 h after subcutaneous administration (Fig.). No differences in locomotion behavior are observed in mice 24 h after ketamine treatment relative to baseline (Fig.). We pooled 1332 neurons from 12 mice, and found that compared to the baseline condition, ~95% of these neurons exhibited increased activity 24 h following ketamine treatment (Fig.). The in vivo calcium event frequencies of these excitatory neurons in mPFC significantly increase (Fig.. linear mixed effect model: overall, p = 3.66 × 10 -5 ). Both calcium event peak amplitudes and integrated calcium event amplitudes in mPFC excitatory neurons show significant increases as well at 24 h following the ketamine treatment (Fig.. linear mixed effect model: overall, p = 0.0003) (Fig.: linear mixed effect model: overall, p = 0.0001). These in vivo imaging results support the hypothesis that ketamine administration results in cortical disinhibition in mPFC.

MOBILITY IMMOBILITY

Forced Swim Test 10) and were subjected to the FST 24 hours later (One-way ANOVA: overall p = 0.0289. Two-sample t test: ketamine + saline vs saline p = 0.0257, ketamine + NRG1 vs ketamine+saline p = 0.0351; mean ± SEM). E Wild-type mice were treated with saline (n = 11), HNK (10 mg/kg; s.c.)(n = 14), or HNK plus NRG1 (1 µg/mouse)(n = 10) and were subjected to the FST 24 h later (One-way ANOVA: overall p = 0.0031. Two-sample t test: HNK + saline vs saline p = 0.0076, HNK + NRG1 vs HNK + saline p = 0.0071; mean ± SEM). F Control ErbB4 fl/fl mice were treated with saline (n = 7) or ketamine (10 mg/kg; s.c.)(n = 8) and PV-Cre; ErbB4 fl/fl mice were treated with saline (n = 9) or ketamine (10 mg/kg; s.c.)(n = 9) and tested on the FST 24 hours later (Two-way ANOVA: overall p = 0.0033. Two-sample t test: saline vs ketamine (ErbB4 fl/fl ) p = 0.0041, saline vs ketamine (PV-Cre; ErbB4 fl/fl ) p = n.s.; mean ± SEM). We find no significant effect of genotype. G Schematics for the experimental timelines for the ErbB4 antagonist PD158780. H Wild-type mice were treated with vehicle (n = 10) or PD158780 (10 mg/kg; s.c.) and subjected to the FST 30 min (n = 7), 2 h (n = 8) or 24 h (n = 6) later (Oneway ANOVA: overall p = 0.0421. Two-sample t test: PD158780 vs saline, 30 min. p = n.s., 2 h p = 0.0098, 24 h p = 0.0395; mean ± SEM).

SUSTAINED CORTICAL DISINHIBITION EVOKED BY SUBANESTHETIC KETAMINE

Recent evidence suggests ketamine may induce cortical disinhibition by reducing interneuron activity. To test the effect of ketamine on cortical inhibition in mPFC (Fig.), we performed whole-cell recording of electrically evoked inhibitory postsynaptic currents (IPSCs) in L2/3 excitatory pyramidal neurons. We did this by preferentially activating L5 to L2/3 feedforward projections to L2/3 inhibitory neurons through L5 electrical stimulation (Fig.). To determine if NMDAR inhibition mediates ketamine's effects, we tested both ketamine acutely applied to the slice bath, or an in vivo treatment of the NMDAR antagonist MK-801. Neither bath-applied ketamine nor an MK-801 treatment caused appreciable effects on IPSC amplitudes in L2/3 pyramidal neurons (Fig.). This suggests that it is unlikely that acute NMDAR inhibition significantly modulates inhibitory synaptic inhibition to L2/3 excitatory neurons in mPFC. Since it is proposed that ketamine undergoes metabolism in vivo and its metabolites may mediate ketamine's antidepressant effect, we tested the disinhibitory action of ketamine by injecting mice with subanesthetic ketamine 1 h before preparing mPFC slices for IPSC recording. We find dramatic reductions in evoked IPSC amplitudes in mPFC excitatory cells at 1 h after ketamine treatment, when inhibitory input to L2/3 excitatory cells is ~50% of saline-treated controls (Fig.). We also tested the effect of the major ketamine metabolite HNK on cortical disinhibition; HNK decreases pyramidal IPSCs 24 h after ). E Calcium transient event data from three representative mPFC neurons from two different mice at baseline and 24 h after ketamine treatment. F There is no significant difference in locomotor behavior (normalized distance; cm/ min) 24 h after ketamine treatment. G Frequencies, as determined by events per time (see "Methods" for details), for neurons at baseline and 24 h after ketamine (n = 1260 cells) (linear mixed effect model: overall, p = 3.66 × 10 -5 ; violin plot with median). H Average peak amplitudes for neurons at baseline and 24 h after ketamine (n = 1260 cells) (linear mixed effect model: overall, p = 0.0003; violin plot with median). I Average integrated amplitudes for neurons at baseline and 24 h after ketamine (n = 1260 cells) (linear mixed effect model: overall, p = 0.0001; violin plot with median). Note that we performed multiple time-point imaging from control mice, neural activity levels did not differ at 1 h versus 24 h post saline injection. treatment (Fig.). Previously, we found that bath application of exogenous NRG1 increases excitatory cell IPSCs under conditions in which the cortex has downregulated NRG1 signaling. We then tested if increased NRG1 signaling reverses the disinhibitory effects. Bath application of NRG1 (5 nM) reverses the disinhibitory effects of ketamine and HNK, and increases evoked IPSCs in L2/3 pyramidal neurons treated with in vivo ketamine and HNK (Fig.). Next we examined the sustained actions of ketamine treatment on evoked IPSCs in L2/3 pyramidal neurons in mPFC slices recorded at 24, 48, 72 h and 1 week after a single-dose treatment. The inhibitory input to excitatory pyramidal neurons is significantly reduced at these time points after ketamine treatment (Fig., G, H). Evoked IPSCs then return to baseline levels 1 week after ketamine treatment (Fig.. One-way ANOVA: overall p = 1.77 × 10 -20 . Two-sample t test (adjusted for multiple comparisons): in vivo ketamine vs saline, 1 h p = 5.01 × 10 -9 , 24 h p = 8.54 × 10 -8 , 48 h p = 1.69 × 10 -8 , 72 h p = 1.04 × 10 -8 , 1 week p = n.s.). Ketamine-mediated decreases in evoked IPSCs are acutely reversible with bath application of NRG1 (Fig.). NRG1 effects are quickly eliminated with washout, and NRG1 has no effect on IPSC amplitude in normal control pyramidal neurons that have not been treated with ketamine (Fig.. One-way ANOVA: overall p = 2.4 × 10 -8 . Two-sample t test (adjusted for multiple comparisons): in vivo ketamine vs saline, 1 h p = 1.02 × 10 -6 , 24 h p = 1.81 × 10 -4 , 48 h p = 2.52 × 10 -5 , 72 h p = 0.0015, 1 week p = n.s.). Neither ketamine treatment nor NRG1 has a significant effect on spontaneous IPSCs or paired-pulse ratios (Supplementary Fig.). These findings support that NRG1 signaling underlies the disinhibitory effects of ketamine in the mPFC.

NRG1/ERBB4 SIGNALING IN PV NEURONS REDUCED BY KETAMINE

Next, we asked whether ketamine modulates NRG1/ ErbB4 signaling specifically in PV interneurons. We tested this using translating ribosome affinity purification (TRAP), which allows for the measurement of cell typespecific mRNA expression changes(Fig.). NRG1 and ErbB4 mRNA expression levels were measured from PV+ or Emx1+ neurons that were either PV+ or non-GABA+, respectively (Fig.). Then tissue from mPFC was harvested from mice at 24 h (1 day), 48 h (2 days), 72 h (3 days) or 1 week after ketamine treatment. Expression of NRG1 mRNA in PV cells of control, non-treated mouse mPFC is higher than that of Emx1+ neurons (Fig.). In PV interneurons, but not in Emx1+ neurons, ketamine treatment results in a sustained downregulation of NRG1 mRNA expression which returns to baseline levels only after 3 days (Fig.) (Fig.. One-way ANOVA: overall p = 0.0006. Two-sample t test (adjusted for multiple comparisons): ketamine vs saline, 24 h p = 0.0027, 48 h p = 0.0002). In PV neurons ErbB4 expression is markedly higher than in Emx1+ neurons. ErbB4 mRNA expression does not significantly change in either PV or Emx1+ neurons after ketamine treatment, except for the 1 week time-point for PV cells where ErbB4 was increased (Fig.) (Fig.. One-way ANOVA: overall p = 0.0018. Two-sample t test (adjusted for multiple comparisons): ketamine vs saline, 1week p = 4.55 × 10 -4 ). We then investigated whether ketamine-mediated downregulation of NRG1 mRNA expression in PV neurons in mPFC was associated with increases in molecular correlates of enhanced neural activity and cortical disinhibition. Using immunostaining we measured the levels of phosphorylated cAMP response element transcription factor (pCREB) at 24, 48, 72 h or 1 week after ketamine treatment (Fig.). In response to increased neural activity in excitatory neurons, CREB is phosophorylated at Ser133 (pCREB) resulting in the transcription of genes induced by neural activity. We quantified the levels of pCREB staining in L2/3 of mPFC in ketamine-treated mice. In excitatory neurons pCREB levels are significantly increased and this is sustained for up to 2 days after ketamine treatment (Fig..Linear mixed effect model: (see figure on previous page) Fig.Subanesthetic ketamine evokes sustained cortical disinhibition, which is reversed with NRG1 treatment. A Schematic depicting the medial prefrontal cortex (mPFC) region of mouse brain from which recordings were taken. B Schematic of recording inhibitory postsynaptic currents (IPSCs) in L2/3 pyramidal (PYR) neurons by preferentially activating L5 → L2/3 feedforward projections to L2/3 PV neurons through L5 electrical stimulation. Recorded pyramidal neurons are filled with biocytin for post-hoc morphological confirmation. C Ketamine acutely applied to cortical slice baths does not induce any change in inhibitory inputs to L2/3 pyramidal neurons (n = 9 cells). Ketamine was washed into cortical slices at a bath concentration of 100 µM starting at 15 min before recording, and continuing through recording. D MK-801 in vivo treatment 24 h prior to recording does not induce any change in inhibitory inputs to L2/3 pyramidal neurons (n = 9 cells). MK-801 is injected to animals at a concentration of 0.1 mg/ kg 24 h before recording. E However, ketamine in vivo treatment (10 mg/kg; s.c.) dramatically reduces evoked IPSCs to PYR neurons with acute and sustained long-term effects at 1 h (n = 12 cells), 24 h (n = 8 cells), 48 h (n = 9 cells), 72 h (n = 9 cells), and 1 week (n = 9 cells) following treatment. Ketamine-evoked sustained decreases in IPSCs are acutely reversed with bath application of NRG1 (5 nM). F HNK in vivo treatment (10 mg/kg; s.c.) 24 h before recording, reduces synaptic inhibition to L2/3 pyramidal cells. Bath application of NRG1 (5 nM) then reverses the effect of in vivo HNK treatment and increases inhibitory inputs (n = 8 cells) (Linear mixed effect model: overall, p = 2.09 × 10 -5 ; NRG1 vs base p = 1.92 × 10 -5 , NRG1 vs wash p = 5.3 × 10 -5 ; mean ± SEM). G Summary data of average evoked IPSC amplitudes in L2/3 pyramidal neurons under the specified conditions (saline, 1, 24, 48, and 72 h, and 1 week after ketamine treatment) (One-way ANOVA: overall p = 1.77 × 10 -20 . Two-sample t test (adjusted for multiple comparisons): in vivo ketamine vs saline, 1 h p = 5.01 × 10 -9 , 24 h p = 8.54 × 10 -8 , 48 h p = 1.69 × 10 -8 , 72 h p = 1.04 × 10 -8 , 1 week p = n.s.; mean ± SEM). H Acute NRG1 treatment increases average evoked IPSC amplitudes ratios in L2/3 pyramidal neurons under the specified conditions (control saline, 1, 24, 48, and 72 h, and 1 week after ketamine treatment) (One-way ANOVA: overall p = 2.4 × 10 -8 . Two-sample t test (adjusted for multiple comparisons): in vivo ketamine vs saline, 1 h p = 1.02 × 10 -6 , 24 h p = 1.81×10 -4 , 48 h p = 2.52 × 10 -5 , 72 h p = 0.0015, 1wk p = n.s.; mean ± SEM). For each trial, electrical stimulation (1 ms, 20 µA) was applied, represented by a black tick beneath one example trace. For the example trace, the arrow indicates the current injection response to monitor access resistance during the experiment.

TRAP NEURONS NON-TRAP NEURONS

Anti-GFP Beads Fig.NRG1 expression in PV neurons is reduced by ketamine. A-G Testing the effect of ketamine on NRG1 mRNA expression using TRAP. A A schematic illustration of the translating ribosome affinity purification strategy. Using PV-Cre; fsTRAP mice, translating ribosomes (polysomes) from PV cells (green cells) have EGFP tags from the EGFP-L10 transgene. Lysis of all cells in the PV-Cre; fsTRAP cortex releases both tagged and non-tagged polysomes. The tagged polysomes are selectively captured on an anti-GFP affinity matrix and used for purification of PV-specific mRNAs associated with tagged polysomes. This strategy is also used to purify mRNA from Emx1+ neurons using Emx1-Cre; fsTRAP mice. Mice were treated with saline or ketamine at P56, then sacrificed 24, 48, 72 h or 1 week later for fsTRAP extraction and qPCR analysis. See "Methods" for more information. overall p = 4.3 × 10 -32 , ketamine vs saline, 24 h p = 2.37 × 10 -5 , 48 h = 1.51 × 10 -23 ). The levels of pCREB then returned to baseline levels. PV interneuronal pCREB levels at baseline are very low and are not significantly changed with ketamine treatment. These findings suggest that a single subanesthetic ketamine treatment results in decreased PV NRG1/ErbB4-directed signaling and cortical disinhibition as measured by pCREB immunoreactivity in excitatory neurons.

PV EXCITATORY INPUT LOSS EVOKED BY KETAMINE

In order to determine if excitatory synaptic inputs to PV interneurons are the functional locus regulating ketamine-mediated cortical disinhibition in mPFC, the effects of ketamine treatment on excitatory inputs to PV cells were measured. We mapped the spatial extent and strengths of excitatory input to L2/3 PV interneurons in mPFC using laser-scanning photostimulation (LSPS) in mPFC brain slices(Fig.). The LSPS experimental method is effective for mapping local circuit connections (Supplementary Fig.). It involves first recording from a single neuron (L2/3 PV interneuron), and then spatially restricted UV laser stimulating surrounding cortical sites in a sequential manner in order to evoke action potentials (APs) with glutamate release (Fig.). Recording from the postsynaptic neuron allows us to quantitatively assess the pattern and strength of synaptic inputs to the recorded neuron from photostimulated sites. Experiments were performed in mPFC slices prepared from control mice and in vivo ketamine-treated adult mice at 1, 24, 48, 72 h, and 1 week after treatment. Control PV neurons were found to have robust excitatory inputs from L2/3 and L5 (Fig.). In mice treated with ketamine, the excitatory drive to PV interneurons is dramatically reduced at 1, 24, 48, and 72 h after treatment (Fig., top row, D, E). At 1 week post ketamine treatment, the excitatory inputs to PV neuronsare restored to control levels (Fig.). Therefore, excitatory input to PV interneurons following ketamine treatment is highly reduced, and this effect is sustained for ~1 week. Next we examined if enhancing NRG1 signaling would restore the excitatory input to PV interneurons after ketamine treatment. We first performed baseline recordings, and then applied bath NRG1 to cortical slices for 20 min. Bath NRG1 had no effect on control PV cells that were not treated with ketamine. Neither the local excitatory synaptic input currents nor the direct uncaging responses (as measured by responses to uncaging at perisomatic regions) were altered in non-ketamine-treated control PV cells after NRG1 application (Fig.). In contrast to this, both the excitatory synaptic currents and the direct uncaging responses of PV cells are very strongly enhanced by bath application of NRG1 in ketamine-treated mice at the 1, 24, 48, and 72 h time points (Fig.) (Fig.. Linear mixed effects model (two factors: treatment, time): highly significant. Two-sample t test (adjusted for multiple comparisons): base vs base (control), 1 h p = 0.0057, 24 h p = 2.76 × 10 -4 , 48 h p = 7.54 × 10 -4 , 72 h p = 1.42 × 10 -4 , 1 week p = n.s.; Paired sample t test (adjusted for multiple comparisons): NRG1 vs base, 1 h p = 0.054, 24 h p = 7.23 × 10 -5 , 48 h p = 2.38 × 10 -4 , 72 h p = 1.82 × 10 -4 , 1week p = n.s.) (Fig.. Linear mixed effects model (two factors): highly significant; Two-sample t test (adjusted for multiple comparisons): base vs base (control), 1 h p = 0.0032, 24 h p = 1.96 × 10 -4 , 48 h p = 0.012, 72 h p = 3.77 × 10 -4 , 1 week p = n.s. Paired sample t test (adjusted for multiple comparisons): NRG1 vs base, 1 h p = 0.0095, 24 h p = 2.63 × 10 -4 , 48 h p = 7.95 × 10 -4 , 72 h p = 2.92 × 10 -4 , 1 week p = n.s.). Bath-applied NRG1 does not alter resting membrane potential or intrinsic membrane excitability in PV cells under control conditions or following ketamine treatment (Supplementary Fig.). These findings from the circuit mapping experiments allow us to determine the molecular and circuit locus of ketaminemediated disinhibition in the mPFC (Supplementary Fig.).

DISCUSSION

Our study defines a novel and critical role of NRG1/ ErbB4 signaling in mPFC PV inhibitory interneurons in mediating the acute and sustained antidepressant effects of subanesthetic ketamine. The most commonly used antidepressant medications, including selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and lithium show 3-6 weeks of time lags to reach effective management of clinical depression. The time lag for antidepressant effectiveness is critical because of the risk of suicide in depressed patients. In contrast, ketamine shows both rapid and sustained antidepressant effects. We find that ketamine-induced antidepressant effects are induced by the downregulation of PV-specific NRG1 signaling and the concurrent loss of excitatory inputs to PV cells. We do not yet fully understand the detailed molecular mechanisms for how/why NRG1 downregulation in PV interneurons occurs after ketamine administration. This is a topic for future investigation. It is possible that a specific NRG1 isoform is responsible for our observed effects. Ketamine's effects are blocked by exogenous NRG1 or knockout of its receptor ErbB4 in PV cells. Our findings are supported by the proposal that ketamine's antidepressant effects are mediated by its regulation of neural circuit plasticity. A single treatment of ketamine or its metabolite HNK induces molecular and circuit changes that promote neural plasticity that outlasts the physical presence of these therapeutic reagents. Our work adds to and integrates previous studies toward understanding the mechanism of how ketamine mediates both rapid and sustained antidepressant effects. Ketamine induces BDNF production, which can signal through its receptor TrkB, resulting in activation of mTOR, all of which are implicated in neural plasticity. mTOR signaling then inhibits GSK3, which also regulates neural plasticity and is the target of the mood stabilizer lithium. All of these signaling molecules are regulated by ketamine treatment. However, it is not clear what circuit mechanisms induce these molecular events. It is becoming increasingly apparent that ketamine treatment results in cortical disinhibition. One potential mechanism for the disinhibitory action of ketamine and the induction of plasticity-related molecular events would be ketamine-mediated decreases in interneuronal activity. In this study, we have extended the concept of PV NRG1/ErbB4 signaling, cortical disinhibition and plasticity, which we and others have formulated in the visual cortex, to the mPFC, which is relevant for cognition and mood disorders. NRG1 signaling is critical for maintaining excitatory synaptic inputs onto PV cells, while reductions in PV NRG1/ErbB4 signaling results in cortical disinhibition. We have previously established that exogenous NRG1 rapidly restores excitatory inputs onto deprived PV cells through downstream PKC-dependent activation and AMPA receptor exocytosis. This mechanism is important for cortical plasticity not only in juvenile mice, but in adult mice as well. As PV cells are the most prominent interneuron type in cortex, and as ErbB4 is very highly expressed and localized in PV cells, we believe that this mechanism is highly significant. While the present study focuses on mPFC mechanisms, systemic ketamine treatment has global effects on multiple brain regions, including lateral habenula, and other brain areas that likely also contribute to its antidepressant effects. Our data indicate a neural mechanism of ketaminemediated cortical disinhibition that is independent of acute NMDAR antagonism, as neither bath-applied ketamine itself nor MK-801 modulates synaptic inhibition (IPSCs) to L2/3 pyramidal neurons. This is consistent with the proposed NMDAR inhibition-independent mechanism of ketamine's actions. While the IPSC evoked by stimulating layer 5 may involve other types of inhibitory neurons, this does not affect our interpretation of cortical disinhibition. We also find that the ketamine metabolite HNK has NRG1-dependent circuit and behavioral effects. Previous studies have demonstrated that acute NRG1 subcutaneous injection alone in mice has no antidepressant-like effects while longer treatment regimens have measurable effects; depressed patients show a disruption of NRG1 signaling. There has been criticism of the use of the FST to measure depression-like behavior in rodents. We find that subanesthetic ketamine reduces PV NRG1/ErbB4 signaling, and that this cotracks a reduction in excitatory input to PV cells, resulting in sustained cortical disinhibition in mPFC. While our data show a reduction of excitatory input to PV neurons, we have not directly examined inhibitory input to PV cells. However, we reason that the overall ketamine effect is to reduce PV neuron activity as reflected by cortical disinhibition in vivo and in vitro (Figs.and). Using in vivo 2-photon calcium imaging, we have previously demonstrated a reduction of in vivo PV neuron activity in visual cortex. Ketamine-mediated antidepressant effects in the FST depend on PV NRG1/ErbB4 signaling. Our new findings present a critical role for PV NRG1/ErbB4 signaling in the antidepressant effect of subanesthetic ketamine (see figure on previous page) Fig.Ketamine induces a sustained loss of excitatory inputs to PV neurons, which is restored with NRG1. A Schematic depicting the medial prefrontal cortex (mPFC) region of mouse brain from which recordings were taken. B Schematic of laser-scanning photostimulation (LSPS) mapping of cortical synaptic connections to individually recorded PV neurons in mPFC slices. LSPS maps the broad spatial pattern of synaptic inputs to the neuron of interest, and distinguishes direct uncaging responses (1, red) to assess glutamate-mediated excitability/responsiveness at perisomatic locations, and synaptically mediated EPSC responses (2, cyan) to assess synaptic inputs from presynaptic neuronal spiking. Cortical layers of 1, 2/3, 5, and 6 in the brain slice are indicated as L1, L2/3, L5, and L6. Recorded PV neurons are filled with biocytin for post-hoc confirmation. C Groupaveraged, excitatory input maps of PV cells recorded at the specified conditions. White circles in each map represent individual PV neurons. The color scales code integrated excitatory input strength (blue = low, red = high) and applies to all other maps in the same condition. C (left column) An acute bath application of NRG1 (5 nM) does not significantly modulate local excitatory synaptic inputs onto PV neurons in mPFC of saline-treatment control mice. Averaged excitatory input maps of L2/3 PV cells are shown before (top), during bath NRG1 (20 min after NRG1 application) (middle), and after washout of bath NRG1 (bottom). C (right columns) Reduced excitatory inputs to PV neurons are seen at 1, 24, 48, and 72 h after ketamine treatment (10 mg/kg; s.c.), but not after 1 week. Excitatory inputs to PV neurons in ketamine-treated mice are restored by acute bath application of NRG1. This acute restoration by NRG1 is eliminated by washout of the bath NRG1. D Summary data of average total synaptic input strength measured for L2/3 PV neurons under the specified conditions (control, 1, 24, 48, and 72 h and 1 week after ketamine treatment) (Linear mixed effects model (two factors): highly significant. Two-sample t test (adjusted for multiple comparisons): base vs base (control), 1 h p = 0.0057, 24 h p = 2.76 × 10 -4 , 48 h p = 7.54 × 10 -4 , 72 h p = 1.42 × 10-4 , 1 week p = n.s. Paired sample t test (adjusted for multiple comparisons): NRG1 vs base, 1 h p = 0.054, 24 h p = 7.23 × 10 -5 , 48 h p = 2.38 × 10 -4 , 72 h p = 1.82 × 10 -4 , 1week p = n.s.; mean ± SEM). E Direct uncaging responses before and during bath NRG1 for PV neurons in control versus ketamine-treated mice. Peak direct responses were measured, which are not affected by overriding synaptic inputs (Linear mixed effects model (two factors): highly significant; Two-sample t test (adjusted for multiple comparisons): base vs base (control), 1 h p = 0.0032, 24 h p = 1.96 × 10 -4 , 48 h p = 0.012, 72 h p = 3.77 × 10 -4 , 1wk p = n.s.; Paired sample t test (adjusted for multiple comparisons): NRG1 vs base, 1 h p = 0.0095, 24 h p = 2.63 × 10 -4 , 48 h p = 7.95 × 10 -4 , 72 h p = 2.92 × 10 -4 , 1 week p = n.s.; mean ± SEM). treatment, providing a compelling molecular and circuit mechanism for ketamine-mediated cortical disinhibition and plasticity (Supplementary Fig.). Taken together, we establish a PV inhibitory neuron-directed molecular and circuit mechanism to account for ketamine's rapid and sustained effects on cortical plasticity that contributes to a better understanding of depression and related affective disorders.

ANIMALS

All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee of the University of California, Irvine. To enable PV-specific labeling and mRNA expression analysis, PV-IRES-Cre knock-in (Jackson Laboratory, stock #008069) mice were crossed to fsTRAP mice(Jackson Laboratory, stock #022367) to generate PV-Cre +/-; fsTRAP mice, in which translating polyribosomes of PV cells are tagged with EGFP from the GFP-L10 transgene. To enable excitatory neuron labeling and mRNA expression analysis, Emx1-Cre mice were crossed to fsTRAP mice to generate Emx1-Cre +/-; fsTRAP mice. Emx1 is predominantly expressed in cortical excitatory neurons. For all experiments, mice were hemizygous for both transgenes. To genetically label PV cells PV-Cre mice were crossed with Ai9 tdTomato reporter knock-in mice (Jackson Laboratory, stock #007905). To generate ErbB4 conditional knockout mice, mice homozygous for loxP-flanked alleleswere crossed with PV-Cre mice to produce PV-Cre +/-; ErbB4 flx/+ mice. These mice were then crossed back to the homozygous loxP-flanked ErbB4 mice to produce PV-Cre +/-; ErbB4 flx/flx mice. The animals (2-5 mice per cage) were housed in a vivarium room with a 12-h light/dark cycle with access to food and water ad libitum. All behavioral experiments were performed between 9 and 12 a.m. Please see Supplementary Tablefor detailed experimental and animal information. The mice were randomly assigned to groups with treatment of either saline or subanesthetic ketamine. A single treatment of ketamine (10 mg/kg, s.c., ketamine hydrochloride; VedCo., Inc.) was used for all the experiments. The (2R, 6R)-HNK dosage (10 mg/kg; Tocris Bioscience) of the published studywas used for our in vivo HNK treatment. For some experiments, we performed in vivo exogenous NRG1 treatment (1 µg per mouse) via subcutaneous administration of recombinant NRG1 containing only the EGF core domain of NRG1-β1 (R&D systems). This form of NRG1 has been shown previously to penetrate the blood-brain barrier and functionally activate ErbB4 in the cortex. For PD158780 (Tocris) experiments, mice were either injected with drug (10 mg/kg; s.c.) or with vehicle (s.c.) containing 10% Tween 80, 20% DMSO, and 70% saline before testing.

FORCED SWIM TEST

For the FST, mice were habituated in the behavior room for 1 h before testing. Mice were then placed individually in a transparent glass cylinder containing water (24 cm high, 14.5 cm diameter, 14 cm water depth) at 23-25 °C and forced to swim. Mice were videotaped for 6 min, and the immobility time (time spent passively floating) was recorded for the last 4 min, after discarding activity in the first 2 min during which an animal tries to escape and habituates to the cylinder. ANY-MAZE software was used to record and analyze immobility (Stoelting Co.). Manual scoring of immobility was also confirmed by a blind experimenter. Immobility times were yielded by subtracting mobility time from the 4 min total testing time.

MINISCOPE IMAGING EXPERIMENTS

At 2 weeks after AAV1-CaMKII-GCaMP6f injection, a gradient refractive index (GRIN) lens was implanted at the injection site in the mPFC as previously described by ref.. A circular craniotomy was centered at the coordinates for the mPFC injections site. ACSF was repeatedly applied to the exposed tissue, and the dura was carefully removed. Cortex below the craniotomy was aspirated. The GRIN lens (0.25 pitch, 0.55 numerical aperture, 1.8-mm diameter and 4.31 mm in length, Edmund Optics) was slowly lowered at an oblique angle (Fig.) using a stereotaxic arm to mPFC. Next, a skull screw was used to anchor the GRIN lens to the skull. Both the GRIN lens and skull screw were fixed with cyanoacrylate and dental cement. Kwik-Sil (World Precision Instruments) was used to cover the lens. Two weeks later, a small aluminum baseplate was cemented onto the head of the animal atop the existing dental cement. A miniscope was fitted into the baseplate and locked in a position so that the field of view was in focus to visualize GCaMP6f-expressing neurons and visible landmarks, such as blood vessels. For behavioral experiments involving mPFC, mice were first handled for 10 min per day for a week in order to allow the animals to become comfortable with the behavioral experimenter. Then animals were habituated to the behavioral arena for 10 min per day for 2 days without a miniscope. Behavior was performed in a quiet designated behavioral room under low lighting conditions (<20 lux). The behavioral arena was 35 cm × 25 cm in size with bedding which was changed between animals. Animals were then habituated to the behavioral arena with the miniscope fixed onto their head while they behaved freely for 10 min per day for 3 days, so that animals were acclimated and habituated to the behavioral experimenter, arena, and miniscope gear. After preparations were completed, in vivo GCaMP6-based calcium imaging of population mPFC neurons was performed in awake freely behaving mice. Behavioral recording were made by tracking the location of the LED on the miniscope through the experimental sessions. Sessions were 5-10 min in length. Using the behavioral tracking video data, the position and speed of the animal was determined using a custom Matlab script. Please refer to previous publicationsand www. miniscope.org/ for technical details of our customconstructed miniscopes. The head-mounted scope has a mass of about 3 g and uses a single, flexible coaxial cable to carry power, control signals, and imaging data to custom open-source data acquisition (DAQ) hardware and software. Under our experimental conditions, the miniscope has a 700 μm × 450 μm field of view with a resolution of 752 pixels × 480 pixels (~1 μm per pixel). The electronics packaged the data to comply with the USB video class protocol and then transmitted the data over Super-Speed USB to a PC running custom DAQ software. The DAQ software was written in C++ and uses Open Computer Vision libraries for image acquisition. Images were acquired at ~30 frames/s and recorded to uncompressed.avi files. The DAQ software simultaneously records the behavior of an animal through a highdefinition webcam (Logitech) at ~30 frames/s, with time stamping of both video streams for offline alignment. Miniscope videos were first concatenated and downsampled by a factor of two using NIH ImageJ software, and then motion-corrected using the NoRMCorre MATLAB package. Next, we visually inspected the maximum intensity projection images of individual video sessions and manually performed minor linear translations to align videos. Then, we created a large combined dataset by concatenating all aligned video images. While this large data concatenation required significant computer resources (that is, 28 cores, 128 GB dynamic random-access memory, 1 TB solid state drive, 8 TB hard disk drive), it greatly enhanced our ability to obtain cell tracking from different days. Subsequent analysis was performed using custom Matlab scripts. We adopted the newly developed method of extended constrained nonnegative matrix factorization for endoscopic data (CNMF-E)to extract the calcium activity of individual neurons. The CNMF-E is based on the CNMF framework, which enables simultaneously denoising, deconvolving and demixing of calcium imaging data. Its key features include modeling the large rapidly fluctuating background that has a low spatial-frequency structure and allows good separation of single-neuron signals from this background. After iteratively solving a constrained matrix factorization problem, CNMF-E extracts the spatial footprints of neurons and their associated temporal calcium signal traces. Specifically, the first step of estimating the temporal activity of a neuron (neuron.C is a denoised version of dF, which is the change of the fluorescence intensity over time) is computing the weighted average of fluorescence intensities after subtracting the temporal activity of other neurons within the region of interest of that neuron. Then, a deconvolution algorithm, OASIS, was applied to obtain the deconvolved calcium event activity (neuron.S). To reduce the number of false discoveries, a noted problem with CNMF-E, we used SCOUT, which applies a linear classifier to the proposed pixel intensity spatial footprints for each neuron, at each iteration. Proposed footprints were normalized and compared with a family of predefined probability distributions, believed to accurately describe typical neuron footprints. Amplitudes were calculated as follows: (1) For each cell, the peak values of calcium events that exceed 0.1*max (calcium peak values) were found, (2) the peak values (neuron.S (dF)) were measured. Integrated amplitudes were calculated as the summation of the integrated area under the calcium event signal (neuron.C (dF)).

TRANSLATING RIBOSOME AFFINITY PURIFICATION (TRAP)

Purification of polysomally bound mRNA from prefrontal cortical lysate was performed as described with modifications. Briefly, mPFC was dissected in ice-cold ACSF (in mM: 126 NaCl, 2.5 KCl, 26 NaHCO 3 , 2 CaCl 2 , 2 MgCl 2 , 1.25 NaH 2 PO 4 , and 10 glucose). The entire mPFC region was dissected out from both hemispheres of each mouse, using a brain block and scalpel. Pooled cortex from 2 to 5 mice was grinded to powder on dry ice, followed with sonication for 5 s in ice-cold lysis buffer [20 mM HEPES (pH 7.4), 150 mM KCl, 5 mM MgCl 2 , 0.5 mM dithiothreitol, 100 μg/ml cycloheximide (Sigma-Aldrich), protease inhibitors (Roche) and 40 U/mL recombinant RNase inhibitor (Promega, Madison, WI)]. Homogenates were centrifuged for 10 min at 2000 × g, 4 °C, to pellet nuclei and large cell debris, and NP-40 (Invitrogen, Carlsbad, CA) and DHPC (Avanti Polar Lipids, Alabaster, Alabama) were added to the supernatant at final concentrations of 1% (vol/vol) and 30 mM, respectively. After incubation on ice for 5 min, the lysate was centrifuged for 10 min at 20,000 × g to pellet insoluble material. Three hundred microliters of the streptavidin Myone T1 dynabeads was bound to 120 μg biotinylated protein L first, then followed with two mouse monoclonal anti-GFP antibodies incubation (Htz-GFP19C8 and Htz-GFP19F7 (50 μg each, Memorial Sloan-Kettering Monoclonal Antibody Facility, New York, NY)). After being washed twice with the polysome extraction buffer, the beads were then added to the cell-lysate supernatant, and the mixture was incubated at 4 °C with end-over-end rotation overnight. The beads were subsequently collected on a magnetic rack and washed four times with high-salt polysome wash buffer [20 mM HEPES (pH 7.4), 350 mM KCl, 5 mM MgCl 2 , 1% NP-40, 0.5 mM dithiothreitol and 100 μg/mL cycloheximide]. RNA was eluted from the beads by incubating beads in RLT buffer (RNeasy Micro Kit, Qiagen, Venlo, Netherlands) with β-mercaptoethanol (10 μL/mL) for 5 min at room temperature. Eluted RNA was purified using RNeasy Micro Kit (Qiagen) per the manufacturer's instructions including in-column DNase digestion. Immunoprecipitated RNA yield for each sample was ~20 ng/μL. For PV-Cre; fsTRAP experiments, both cortices (mPFC) from 5 mice were pooled together to generate n = 1 before mRNA extraction. For Emx1-Cre; fsTRAP experiments both cortices (mPFC) from two mice were pooled together to generate n = 1 before mRNA extraction.

QUANTITATIVE REAL-TIME POLYMERSE CHAIN REACTION (QPCR)

Purified RNA (30 ng) was converted to cDNA using Superscript ® III reverse transcriptase (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Quantitative changes in cDNA levels were determined by real-time PCR using the Power SYBR Green Master Mix (Thermo Fisher Scientific, Waltham, MA, USA), using primers at a concentration of 500 nM. Primers were custom designed for mouse NRG1, ErbB4, and for the endogenous control GAPDH. Primers for NRG1 are specific for the "total" form, which represents all known transcript variants. PCR was carried out for 2 min 50 °C, 5 min 95 °C, 40 cycles (15 s for 95 °C, 30 s for 50 °C), followed by a melt curve. Technical triplicates were used. Technical triplicates were averaged together to produce a single Ct value for each gene of each sample. GAPDH was used to normalize gene expression and data presented at mean ± SEM. Cycling and quantitation were performed on a ViiA™ 7 Real-Time PCR System instrument (Thermo Fisher Scientific, Waltham, MA, USA) using the ViiA 7 software v1.2. The following primers were used: NRG1-F GCAAGTGCCCAAATGAGTTTAC; NRG1-R GCTCCTCCGCTTCCATAAAT; ErbB4-F CAT GGCCTTCCAACATGACTCTGG; ErbB4-R GGCAGTG ATTTTCTGTGGGTCCC; GAPDH-F CATCACTGCCA CCCAGAAGACTG ; GAPDH-R ATGCCAGTGAGCTT CCCGTTCAG.

IMMUNOHISTOCHEMISTRY

For immunochemical staining experiments, animals were first deeply anesthetized with Uthasol (sodium pentobarbital, 100 mg/kg, i.p.) and were then perfused transcardially with 5 mL of 1× phosphate buffered saline (PBS, pH 7.3-7.4), followed by 20 mL 1× PBS containing 4% paraformaldehyde (PFA) and phosphatase inhibitor (PhosSTOP, 1 tablet for 20 mL, Roche, Switzerland). Brains were removed and maintained in 4% PFA for 24 h, and then transferred to 30% sucrose in 1× PBS for 24 h. Then, using a freezing microtome (Leica SM2010R, Germany), coronal sections of the brain were taken at a 30 µm thickness. Mouse mPFC coronal sections were used for immunohistochemical staining and analysis. Free floating sections were rinsed five times with 1× PBS, and incubated in a blocking solution for 1 h at room temperature on a shaker. The blocking solution contained 5% normal donkey serum and 0.25% Triton X in 1× PBS. Sections were then incubated with the primary antibody diluted in blocking solution for 36 h at 4 °C. After incubation with the primary antibody, brain sections were rinsed thoroughly with 1× PBS, and then incubated with the secondary antibody diluted in blocking solution for 2 h at room temperature. After the secondary antibody was rinsed off, sections were counterstained with 10 µM 4′-6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, St. Louis, MO) for 5 min to help distinguish cortical laminar structure and neuronal nuclei. Lastly, sections were rinsed and then mounted on microscope slides. Sections were cover-slipped with Vectashield mounting medium (H-1000, Vector, Burlingame, CA). To identify PV-positive neurons in PV-Cre; fsTRAP mice, the primary goat anti-PV antibody (PVG-213, Swant, Switzerland; RRID: AB_10000345; 1:1000) and a Cy3-conjugated donkey antigoat antibody (Jackson ImmunoResearch, 1:200) were used. To identify GABA positive neurons in Emx1-Cre; fsTRAP mice, the primary rabbit anti-GABA antibody (Sigma-Aldrich, 1:1000) and a Cy3-conjugated donkey anti-rabbit antibody (Jackson ImmunoResearch, 1:200) were used. To identify pCREB positive neurons, the primary rabbit anti-pCREB antibody (Cell Signaling, 1:1000) was used. Immunostained sections were examined, and 10× and 40× image stacks were acquired using a confocal microscope (LSM 780, Carl Zeiss Microscopy, Germany). Image tiles, overlaying, maximum projections, and subset z-stack selections were performed using the Zeiss image processing software (ZEN). For fluorescent imaging, all sections of a staining series were acquired using the same settings (laser power, pinhole size, line scans), and data images were digitally processed identically. Individual cell fluorescence measurements (immunofluorescence) are performed in final output images using Adobe Photoshop software (CS4 extended version, Adobe Systems, San Jose, CA). PV or putative excitatory neurons with clear somata in mPFC regions are selected; the cell areas (number of pixels) and their integrated density (whole-cell fluorescence intensity) are measured. The background reading of the fluorescence level is determined for each stained mPFC section image. The corrected total fluorescence per cell in arbitrary units is calculated in an Excel sheet by applying the measurements obtained from the analyzed cell with the formula: Corrected total cell fluorescence = Integrated density -(Area of selected cell × mean fluorescence of background reading). For immunostaining fluorescence quantification, the staining intensities (measured by corrected total fluorescence) of PV and non-PV neurons from individual mice (1-2 sections per mouse) in each group are quantified; the mean values with all examined neurons per each mouse are calculated. These mean values are normalized to the specified mean for the control condition in the same staining series. The overall normalized values from different mice were compared across different conditions.

ELECTROPHYSIOLOGY AND LASER-SCANNING PHOTOSTIMULATION

Coronal sections (400 µm thick) of mPFC were cut from mouse with a vibratome (VT1200S, Leica Biosystems, Buffalo Grove, IL) in sucrose-containing ACSF (85 mM NaCl, 75 mM sucrose, 2.5 mM KCl, 25 mM glucose, 1.25 mM NaH 2 PO 4 , 4 mM MgCl 2 , 0.5 mM CaCl 2 , and 24 mM NaHCO 3 ). Slices were incubated for at least 30 min in sucrose-containing ACSF at 32 °C before being transferred into slice-recording chambers with standard ACSF (126 mM NaCl, 2.5 mM KCl, 26 mM NaHCO 3 , 2 mM CaCl 2 , 2 mM MgCl 2 , 1.25 mM NaH 2 PO 4 , and 10 mM glucose). Throughout the cutting, incubation and recording, the solutions were continuously supplied with 95% O 2 to 5% CO 2 . We have previously described our methods for electrophysiological recording, imaging, and photostimulation in detail, including the definitions of all reported parameters. For our more recent publications using these same methods see refs.. Briefly, whole-cell recordings were performed in oxygenated ACSF at room temperature under a differential interference contrast/fluorescent Olympus microscope (BX51WI). Oxygenated ACSF was fed into the slice-recording chamber through a custom-designed flow system, driven by pressurized 95% O 2 to 5% CO 2 (3 PSI) with a perfusion flow rate of about 2 mL/min. Slices were first carefully examined under a 4× objective for targeting either L2/3 PV interneurons that express red fluorescent protein or tdTomato or pyramidal neurons within the mPFC. To perform whole-cell recordings, neurons were visualized at high magnification (60× objective, 0.9 NA; LUMPlanFl/IR, Olympus America Inc). The cell bodies of recorded neurons were at least 50 µm below the surface of the slice. Patch pipettes (4-6 MΩ resistance) made of borosilicate glass were filled with an internal solution containing 126 mM K-gluconate, 4 mM KCl, 10 mM HEPES, 4 mM ATP-Mg, 0.3 mM GTP-Na, and 10 mM phosphocreatine (pH 7.2, 300 mOsm) when measuring excitatory postsynaptic currents (EPSCs) at -70 mV. The electrodes also contained 0.1% biocytin for post-hoc cell labeling and further morphological labeling. Once stable whole-cell recordings were achieved with good access resistance (<30 MΩ), basic electrophysiological properties were examined through depolarizing and hyperpolarizing current injections. Electrophysiological data were acquired with a Multiclamp 700B amplifier (Molecular Devices), data acquisition boards (models PCI MIO 16E-4 and 6713, National Instruments), and a custom-modified version of Ephus software 5. Data were digitized at 10 kHz. Any recordings in which the access resistance changed by >20% during the course of the experiment were excluded from analysis. In separate experiments, a cesium-based internal solution containing 130 mM CsOH, 130 mM d-gluconic acid, 0.2 mM EGTA, 2 mM MgCl 2 , 6 mM CsCl, 10 mM HEPES, 2.5 mM ATP-Na, 0.5 mM GTP-Na, and 10 mM phosphocreatine (pH 7.2, 300 mOsm) was used to voltage clamp pyramidal neurons at the excitatory reversal potential (0-5 mV) and measure IPSCs. Electrically evoked inhibitory postsynaptic currents (IPSCs) in L2/3 excitatory pyramidal neurons were recorded by preferentially activating L5 to L2/3 feedforward projections to L2/3 inhibitory neurons through L5 electrical stimulation (Fig.). During photostimulation experiments, the microscope objective was switched from 60× to 4× for laser-scanning photostimulation. The same low-power objective lens was used for delivering ultraviolet flash stimuli. Stock solution of MNI-caged-l-glutamate (Tocris Bioscience) was added to 20 mL of circulating ACSF for a concentration of 0.2 mM caged glutamate. The cortical slice image, acquired through the 4× objective, was visualized using a high-resolution digital CCD camera, and this was in turn was used for guiding and registering photostimulation sites. A laser unit (DPSS Lasers) was used to generate 355 nm UV laser pulses for glutamate uncaging. Short pulses of laser flashes (1 ms, 20 mW) were delivered using an electro-optical modulator and a mechanical shutter. Focal laser spots approximated a Gaussian profile with a diameter of ~50-100 μm. Voltage clamping the recorded neuron allowed determination of sites contributing direct synaptic input. By systematically surveying synaptic inputs from hundreds of different sites across a large region, aggregate synaptic input maps were generated for individual neurons. For our mapping experiments, a standard stimulus grid (16 × 16 stimulation sites, 65 µm 2 spacing) was used to tessellate mPFC from pia to white matter. The LSPS site spacing was empirically determined to separate adjacent stimulation sites by the smallest predicted distance in which photostimulation differentially activated adjacent neurons. Glutamate uncaging laser pulses were delivered sequentially in a nonraster, nonrandom sequence, following a "shifting-X" pattern designed to avoid revisiting the vicinity of recently stimulated sites. Because glutamate uncaging agnostically activates both excitatory and inhibitory neurons, we empirically determined the excitatory and inhibitory reversal potentials in L2/3 pyramidal cells to properly isolate EPSCs and IPSCs. We voltage clamped PV and pyramidal cells at -70 mV to determine LSPS evoked EPSCs. Photostimulation induces two kinds of excitatory responses: (1) responses that result from direct activation of the recorded neuron's glutamate receptors, and (2) synaptically mediated responses (EPSCs) resulting from the suprathreshold activation of presynaptic excitatory neurons. Responses that occur within 10 ms of the laser pulse onset are considered direct; these responses exhibit a distinct waveform and occur immediately after glutamate uncaging. Synaptic currents with such short latencies are not possible because they would have to occur before the generation of APs in photostimulated neurons. Therefore, direct responses are excluded from local synaptic input analysis, but they are used to assess glutamate-mediated excitability/responsiveness of recorded neurons. At some locations, synaptic responses override the relatively small direct responses, and these responses are identified and included in synaptic input analysis. For data map analysis, we implement the approach for detection and extraction of photostimulation-evoked postsynaptic current responses described in ref.. LSPS evoked EPSCs are quantified across the 16 × 16 mapping grid for each cell, and 2-4 individual maps are averaged per recorded cell, reducing the likelihood of incorporating noise events in the analysis window. The EPSC input from each stimulation site is the measurement of the sum of individual EPSCs within the analysis window (>10 ms to 160 ms post photostimulation), with the baseline spontaneous response subtracted from the photostimulation response of the same site. The value is normalized with the duration of the analysis window (i.e., 150 ms) and expressed as average integrated amplitudes in picoamperes. The analysis window is used because photostimulated neurons fire most of their APs during this time. For the color-coded map displays, data are plotted as the average integrated EPSCs amplitude per pixel location (stimulation site), with the color scale coding input strength. For the group maps obtained across multiple cells, the individual cell maps were first aligned by their slice images using laminar cytoarchitectonic landmarks. Then a new map grid is created to resample and average input strength at each site location across cell maps; a smooth version of color-coded map is presented for overall assessments. To further quantitatively compare input strength across cell groups or different conditions, we measure the total ESPC inputs across all map sites (total synaptic input strength) for individual cells. For the experiments that examined the effects of bath application of NRG1, MK-801, ketamine or HNK, the reagent(s) were added into the ACSF solution with the specified concentrations. The drug application for 20 min was estimated to produce full effects, while the washout of 20-30 min was considered to remove the added drug from the recording solution.

STATISTICAL ANALYSIS

Data analysis was conducted using Matlab and R. Because the data presented in this article were collected using different experimental designs, several appropriate statistical tests were applied in the data analysis. This included ANOVA, t-test, Kruskal-Wallis test, Friedman's test, Mann-Whitney U test, Wilcoxon signed rank test, linear mixed effect model, and Bonferroni correction for multiple comparisons.

LINEAR MIXED EFFECT (LME) MODEL

The LME model is a commonly used method to deal with repeated measures. Its importance has been increasingly recognized in analyzing calcium imaging data. We use LME in the presence of repeated measures. For example, the 1535 cells (observations) presented in Fig.were from 24 mice. To account for random effects due to mice, we fit a linear mixed effects model where the random effect variable is mouse IDs. More complicated examples are the analyses we conducted for Figs.. Take Fig.as an example, 1332 cells were taken from 12 mice and each cell was measured twice, one at baseline and the other after ketamine treatment. Because there are repeated measures for each cell and cells are nested in mice, we fit an LME with nested random effects.

NORMALITY AND NONPARAMETRIC TESTS

When normality does not hold or sample sizes are small, parametric results might not be accurate. For the results reported in the paper, we verified them by using nonparametric tests. Specifically, we substituted Kruskal-Wallis test for one-way ANOVA, Mann-Whitney U test for twosample t test, Wilcoxon signed rank test for paired t test, Friedman's test and its modified version for repeated measures one-way ANOVA. In most situations, the p values based on nonparametric tests are greater than those from parametric tests but the trends and conclusions remain valid.

MULTIPLE COMPARISONS

When there is more than one hypothesis test, appropriate adjustments are necessary to gauge claimed type I error rates and thereby to generate replicable research findings. The Bonferroni correction, which multiplies each p value by the number of tests considered, is a simple and stringent method to control familywise type I error rate. When the number of tests in a figure is a concern (e.g., more than two tests), we correct p values using the Bonferroni's correction.

SOFTWARE

The analysis was done using custom-written scripts in Matlab and R.

Full Text PDF

Open PDF in new tab

Study Details

Your Library